Experts Pan Administration’s Drug Pricing Executive Orders

In executive orders released July 24, the Trump administration renewed its push toward a signature campaign issue: lowering drug prices. However, experts say that the orders are a rehash of similar proposals by the administration that failed to gain backing from either political party in 2019, and they are skeptical of the idea that the orders will actually lower prices.

The three executive orders call for regulations allowing drugs to be imported from other countries, requiring Federally Qualified Health Centers (FQHCs) to make insulin and epinephrine available to low-income members of the public at the discounted prices set by the 340B Drug Pricing Program, and removing safe harbor protections under the Anti-Kickback Statue for prescription drug rebates in Medicare Part D.

0 Comments
© 2022 MMIT
Peter Johnson

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

call-center
May 20

Marketplace, MCOs Will Face a Rocky Transition When PHE Ends

READ MORE
exec-pointing-at-graphs
May 20

Startups Oscar Health, Bright Health Exit Markets & Tighten Belts

READ MORE
humana-logo
May 20

Humana Doubles Down on Primary Care Clinic Investments

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today